The financials
Sotera Health Company by the numbers
Sotera Health Company (SHC) reported revenue of $321M in Q2 2026 (quarter ended June 30, 2026), up 9.2% from the same quarter a year earlier. That came with a gross margin of 55% and net income of $54M (17% of revenue). For the full year FY2025, revenue was $1.16B (+5.7% year on year) and net income $78M. Its largest segment in 2026-Q2 was Sterigenics at $212M, 82% of the disclosed total, just ahead of Nordion at 18%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $321M | $294M | +9.2% |
| Gross profit | $178M | $167M | +6.8% |
| Net income | $54M | $8.0M | +574% |
| Diluted EPS | $0.19 | $0.03 | +533% |
| Operating | Revenue | Share |
|---|---|---|
| Sterigenics | $212M | 82% |
| Nordion | $47M | 18% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $258.8M (+14%)
Nordion grew +14% year on yearSterigenics +8.6% year on year
Segment Latestquarter on quarteryear on year
- Sterigenics$211.6M$211.6MQoQ +14%year on year +8.6%+14%+8.6%
- Nordion$47.2M$47.2MQoQ +15%year on year +14%+15%+14%
- Nelson Labs$0.00$0.00QoQ -year on year ---
Diagnostics & Research
Ranks #18 of 29 by Smart Score